s6y

Q/C TECHNOLOGIES, INC.

Ticker
QCLS
CIK
1321834
Industry
In Vitro & In Vivo Diagnostic Substances
Formerly
Q/C TECHNOLOGIES, INC., TNF Pharmaceuticals, Inc., MyMD Pharmaceuticals, Inc., Akers Biosciences, Inc., Akers Biosciences Inc

Financials 71

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-K/A Annual Report for period ending Dec 31, 2025
  5. 10-K Annual Report for period ending Dec 31, 2025
  6. NT 10-K Notice under Rule 12b25 of inability to timely file all or part of a Form 10-K, 10-KSB, or 10-KT for period ending Dec 31, 2025
  7. 10-Q Quarterly Report for period ending Sep 30, 2025
  8. NT 10-Q Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB for period ending Sep 30, 2025
  9. 10-Q Quarterly Report for period ending Jun 30, 2025
  10. NT 10-Q Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB for period ending Jun 30, 2025

All 71 financials filings

News 169

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K/A Current report filing
  10. 8-K Current report filing

All 169 news filings

Ownership 170

  1. 4 Statement of changes in beneficial ownership of securities
  2. 4/A Statement of changes in beneficial ownership of securities
  3. 3 Initial statement of beneficial ownership of securities
  4. 3 Initial statement of beneficial ownership of securities
  5. 4 Statement of changes in beneficial ownership of securities
  6. 4 Statement of changes in beneficial ownership of securities
  7. 4 Statement of changes in beneficial ownership of securities
  8. 4 Statement of changes in beneficial ownership of securities
  9. 4 Statement of changes in beneficial ownership of securities
  10. 4 Statement of changes in beneficial ownership of securities

All 170 ownership filings

Prospectus 68

  1. S-3 Registration statement for specified transactions by certain issuers
  2. DRS Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
  3. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  4. S-3 Registration statement for specified transactions by certain issuers
  5. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  6. S-3/A Registration statement for specified transactions by certain issuers
  7. S-3 Registration statement for specified transactions by certain issuers
  8. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  9. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  10. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

All 68 prospectus filings

Proxies 38

  1. DEF 14A Definitive proxy statements
  2. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  3. DEFR14A Definitive revised proxy soliciting materials
  4. PRER14A Preliminary revised proxy soliciting materials
  5. DEF 14A Definitive proxy statements
  6. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  7. DEF 14A Definitive proxy statements
  8. DEF 14A Definitive proxy statements
  9. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  10. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.

All 38 proxies filings

Other 90

  1. EFFECT Notice of Effectiveness
  2. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  3. UPLOAD Letter (PDF)
  4. EFFECT Notice of Effectiveness
  5. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  6. SCHEDULE 13D/A
  7. UPLOAD Letter (PDF)
  8. D Exempt (Private) Offering
  9. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  10. UPLOAD Letter (PDF)

All 90 other filings